

Protalix BioTherapeutics, Inc.
Form 8-K
January 05, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): January 5, 2015

Protalix BioTherapeutics, Inc.

(Exact name of registrant as specified in its charter)

Florida 001-33357 65-0643773
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)

2 Snunit Street 20100
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code +972-4-988-9488

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On January 5, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing the Company’s newly implemented strategy for accelerated growth. The release includes an estimate of the Company’s current cash position. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 8.01. Other Events

As set forth in Item 2.02, on January 5, 2015, the Company issued a press release announcing its newly implemented strategy for accelerated growth.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated January 5, 2015 (disclosure referenced in Item. 2.02 is furnished with this report, not filed).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX
BIOTHERAPEUTICS, INC.

Date: January 5, 2015 By: /s/ Moshe Manor
Name: Moshe Manor
Title: President and
Chief Executive Officer